Immunitas Therapeutics employs a single cell genomics platform to dissect the biology of immune cells in human tumors. They identify novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs.
Amanda Wagner
Longwood Fund
Kai Wucherpfennig, M.D., Ph.D
Mario Suva, M.D., Ph.D
Dane Wittrup, PhD
November 2019